Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209371 · ClinicalTrials.gov registry record · Phase 2
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
A Phase 2 study of IgA Monoclonal Gammopathy of Undetermined Significance, sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07209371 is a Phase 2 study of IgA Monoclonal Gammopathy of Undetermined Significance that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07209371, a Phase 2 study of IgA Monoclonal Gammopathy of Undetermined Significance, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Rifaximin
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07209371
The ClinicalTrials.gov registry entry for NCT07209371 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgA Monoclonal Gammopathy of Undetermined Significance appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT07209371 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT07209371 about?
NCT07209371 is a clinical study titled "Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance". This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and ...
What is the current status of trial NCT07209371?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-01-22. Estimated completion is 2028-05-01.
What conditions does trial NCT07209371 study?
This clinical trial studies the following conditions: IgA Monoclonal Gammopathy of Undetermined Significance.
What interventions are being tested in trial NCT07209371?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT07209371?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209371 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.